Want to see KR:008490 full AI Analyst Report?
Top Page
Suheung Co. Ltd.
(008490)
Select Model
Select Model
Rating:58Neutral
Price Target:
$18,606.00
Action:N/A
Date:10/28/26
The score reflects a stable but only moderate financial profile (improving leverage and better recent cash flow, but weaker margins/returns and mixed cash conversion), weighed down by clearly bearish technical momentum. A very low P/E and reasonable dividend yield materially improve the outlook on valuation.
Positive Factors
Continuing Revenue Growth
Revenue growth continuing through the TTM period and extending expansion since 2023 indicates the company is still broadening its pharmaceutical and healthcare sales base. Although growth has moderated, ongoing top-line expansion can support operating scale and preserve reinvestment capacity over the next several quarters.
Negative Factors
Margin Compression
Profitability remains positive, but the decline in net margins from earlier highs indicates that revenue growth is producing less profit than before. Persistent margin pressure could limit earnings expansion, reduce operating resilience, and constrain the cash available for reinvestment.
Read all positive and negative factors
Positive Factors
Negative Factors
Continuing Revenue Growth
Revenue growth continuing through the TTM period and extending expansion since 2023 indicates the company is still broadening its pharmaceutical and healthcare sales base. Although growth has moderated, ongoing top-line expansion can support operating scale and preserve reinvestment capacity over the next several quarters.
Read all positive factors
Suheung Co. Ltd. (008490) vs. SPDR S&P 500 ETF (SPY)
Market Cap
₩198.48B
Dividend Yield2.8%
Average Volume (3M)11.59K
Price to Earnings (P/E)5.1
Beta (1Y)0.15
Revenue Growth11.64%
EPS Growth-4.94%
CountryKR
Employees769
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)3516.82
Shares Outstanding11,569,113
10 Day Avg. Volume12,600
30 Day Avg. Volume11,590
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.51
Price to Sales (P/S)0.35
P/FCF Ratio6.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1,955
Revenue Forecast (FY)₩725.80B
Suheung Co. Ltd. Business Overview & Revenue Model
Company Description
Suheung Co., Ltd. specializes in the production and provision of empty hard capsules, which are primarily utilized within the pharmaceutical and nutraceutical industries. The company further diversifies its business by offering comprehensive contr...
Suheung Co. Ltd. Financial Statement Overview
Summary
Income Statement
64
Positive
Balance Sheet
58
Neutral
Cash Flow
52
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 765.90B | 722.31B | 653.26B | 594.57B | 634.97B | 596.73B |
| Gross Profit | 134.62B | 123.32B | 103.23B | 99.03B | 137.28B | 126.23B |
| EBITDA | 78.74B | 91.23B | 73.47B | 77.16B | 98.73B | 115.01B |
| Net Income | 39.14B | 43.49B | 18.28B | 6.12B | 33.98B | 53.69B |
Balance Sheet | ||||||
| Total Assets | 1.11T | 1.06T | 1.02T | 993.74B | 926.42B | 809.95B |
| Cash, Cash Equivalents and Short-Term Investments | 71.38B | 58.68B | 49.15B | 48.42B | 58.32B | 34.18B |
| Total Debt | 437.73B | 435.08B | 449.36B | 467.86B | 404.68B | 342.99B |
| Total Liabilities | 529.28B | 520.12B | 509.92B | 516.67B | 456.69B | 380.09B |
| Stockholders Equity | 518.99B | 488.68B | 454.68B | 425.67B | 421.34B | 387.76B |
Cash Flow | ||||||
| Free Cash Flow | 38.74B | 35.98B | 17.46B | -41.77B | -11.27B | 28.64B |
| Operating Cash Flow | 91.19B | 81.57B | 56.16B | 10.49B | 52.91B | 66.85B |
| Investing Cash Flow | -55.85B | -49.93B | -18.08B | -70.17B | -93.45B | -56.79B |
| Financing Cash Flow | -24.54B | -20.48B | -41.10B | 56.99B | 50.52B | -23.23B |
Suheung Co. Ltd. Technical Analysis
Negative
―
Price Trends
20808.60
Negative
20405.80
Negative
20512.20
Negative
Market Momentum
-766.47
Positive
30.83
Neutral
5.88
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:008490, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 19287.50, equal to the 50-day MA of 20808.60, and equal to the 200-day MA of 20512.20, indicating a bearish trend. The MACD of -766.47 indicates Positive momentum. The RSI at 30.83 is Neutral, neither overbought nor oversold. The STOCH value of 5.88 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:008490.
Suheung Co. Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ₩243.17B | 3.39 | ― | 3.64% | 4.13% | 116.32% | |
66 Neutral | ₩225.55B | 10.30 | ― | 4.16% | 0.28% | 16.80% | |
58 Neutral | ₩198.48B | 5.07 | ― | 2.80% | 11.64% | -4.94% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | ₩212.70B | 59.83 | ― | 0.44% | 11.35% | 204.54% | |
52 Neutral | ₩299.64B | 12.56 | ― | 1.57% | 5.50% | -26.11% | |
40 Underperform | ₩173.93B | -28.12 | ― | ― | 0.60% | -6964.46% |
* General Sector Average
KR:008490
Suheung Co. Ltd.
17,850.00
-9,106.65
-33.78%
KR:003520
YUNGJIN PHARM. CO. LTD
951.00
-1,089.00
-53.38%
KR:004310
Hyundai Pharmaceutical Co., Ltd.
6,880.00
3,164.38
85.16%
KR:005500
Samjin Pharmaceutical Co., Ltd.
19,240.00
241.83
1.27%
KR:009290
Kwang Dong Pharmaceutical Co., Ltd.
6,370.00
705.94
12.46%
KR:033270
KOREA UNITED PHARM, INC.
16,760.00
-1,539.97
-8.42%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.